ArticleJournal of clinical medicine2026

Twenty-Four-Month Real-World Outcomes of Ofatumumab in Relapsing-Remitting Multiple Sclerosis: A Multicenter Retrospective Cohort Study.

Weronika Galus et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.